Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 4;31(12):672.
doi: 10.1007/s00520-023-08116-4.

The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus

Brigitte Dreno  1 , Kiarash Khosrotehrani  2 , Giselle De Barros Silva  3 , Julie Ryan Wolf  4 , Delphine Kerob  5 , Mark Trombetta  6 , Etienne Atenguena  7 , Pascale Dielenseger  8   9   10 , Meng Pan  11 , Florian Scotte  12   13 , Ivan Krakowski  14   15 , Mario Lacouture  16
Affiliations
Review

The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus

Brigitte Dreno et al. Support Care Cancer. .

Abstract

Skin toxicities are very common in patients undergoing cancer treatment and have been found to occur with all types of cancer therapeutic interventions (cytotoxic chemotherapy, targeted therapies, immunotherapy, and radiotherapy). Further, skin toxicities can lead to interruption or even discontinuation of anticancer treatment in some patients, translating to suboptimal outcomes. Dermocosmetics (or cosmeceuticals)-defined as skincare solutions incorporating dermatologically active ingredients (beyond vehicle effects) that directly improve symptoms of various skin conditions-are increasingly being used in cancer care to prevent and manage skin toxicities. The active ingredients in these products have a measurable biological action in skin; they typically improve skin integrity (barrier function/hydration and other factors) while relieving skin symptoms. The Association Francophone des Soins Oncologiques de Support (AFSOS) and Multinational Association of Supportive Care in Cancer (MASCC) partnered to select a multidisciplinary group of healthcare professionals involved in the management of patients with cancer and skin toxicities. The group reviewed existing literature and created a summary of recommendations for managing these toxicities through online meetings and communication. In this publication, the group (1) reviews new skin toxicities seen with oncology drugs and (2) evaluates the role of dermocosmetics in improving patient outcomes and minimizing cancer treatment interruptions. We provide general recommendations for initiation and selection of skin care in all oncology patients as well as recommendations for what factors should be considered when using dermocosmetics in specific types of skin toxicities.

Keywords: Anticancer therapeutics; Cancer management; Cosmeceuticals; Dermocosmetics; Oncodermatology; Skin toxicity.

PubMed Disclaimer

Conflict of interest statement

Pr. Dreno has served as consultant/speaker/received honoraria from La Roche Posay, Pierre Fabre, and Galderma; Dr. Khosrotehrani has served as investigator or consultant to La Roche Posay, Novartis, Sanofi, and Eli Lilly; Dr. De Barros Silva has served as investigator or consultant to La Roche Posay, Bio Brazilian Information Oncology, Janssen, and Merck; Dr. Wolf has served as investigator or consultant to La Roche Posay, VisualDx (dba Logical Images), Argentum Medical, and Pfizer; Dr. Kerob is an employee of La Roche-Posay, a L’Oreal company; Dr. Trombetta has nothing to declare; Dr. Atenguena has served as consultant to La Roche Posay and Merck; Ms. Dielenseger has served as consultant to La Roche Posay, Pfizer, Glaxo SmithKline, Astra Zeneca, Merck Sharp & Dohme, Mundi Pharma, and Servier; Dr. Pan has nothing to declare; Dr. Scotte and Dr Krakowski have no conflicts of interest to declare; Dr. Lacouture has a consultant role with Johnson and Johnson, Novocure, Janssen, Novartis, Deciphera, Kintara, RBC/La Roche Posay, Tmunity, Repare, Kinnate, Trifecta, Genentech, Loxo, Seattle Genetics, Lutris, OnQuality, Roche, Oncoderm, and Apricity. Dr. Lacouture also receives research funding from Lutris, Paxman, Novocure, OQL, Novartis, and AZ and is funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.

Figures

Fig. 1
Fig. 1
Steps in managing skin toxicities
See this image and copyright information in PMC

Comment in

References

    1. Lacouture ME, Choi J, Ho A et al (2021) Us cutaneous oncodermatology management (uscom): a practical algorithm. J Drugs Dermatol 20:3s-s19 - PubMed
    1. Deutsch A, Leboeuf NR, Lacouture ME et al (2020) Dermatologic adverse events of systemic anticancer therapies: cytotoxic chemotherapy, targeted therapy, and immunotherapy. Am Soc Clin Oncol Educ Book 40:485–500 - PubMed
    1. Bensadoun RJ, Humbert P, Krutman J et al (2013) Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel. Cancer Manag Res 5:401–408 - PMC - PubMed
    1. Lacouture M, Sibaud V (2018) Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol 19:31–39 - PMC - PubMed
    1. Lee J, Lim J, Park JS et al (2018) The impact of skin problems on the quality of life in patients treated with anticancer agents: a cross-sectional study. Cancer Res Treat 50:1186–1193 - PMC - PubMed